Corcept Therapeutics Incorporated (CORT)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-11-04
$79.22-3.31%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-11-04
Research Workspace
Put CORT beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRevenue growth is accelerating — up about 30% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 22%.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 63% in its worst 12-month stretch.
View RiskCORT's Cushing's disease growth must keep compounding to justify the price. Revenue grew 64% year over year in the latest quarter. The company also beat earnings estimates by 48.5%. It trades at 12x sales versus a 2.3x peer median. This premium is 5.2x higher than the peer group. Management is running behind on a stated commitment. Our model puts the next-quarter miss probability near 46%. Peer multiples imply a price about 5.2x above where it trades. This read is provisional. The thesis is on watch.
Trailing returns as of 2026-11-04. CORT is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 5 analysts currently covering CORT (as of Nov 2026).
Based on 4 Wall Street analysts offering 12-month price targets for CORT in the last 4 months.
Continue this research
Compare CORT with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CORT Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across our valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No fair value published
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
This applies to all three horizons. The trailing multiples, peer comparison, and quality and trajectory reads on this page are unaffected. Names move in and out of this state day to day as the methods converge or diverge. Method agreement on this name is low.
Top 25% on quality vs scored peers
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put CORT next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Increase 2026 revenue guidance to $1.1-$1.2 billion
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $79.22
The last 12 months of price, then the range of analyst 12-month targets from today’s $79.22.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Long-term revenue target supports growth thesis.
Advances: Increase 2026 revenue guidance to $1.1-$1.2 billion
Q3 beat supports revenue growth objective.
Threatens: Increase 2026 revenue guidance to $1.1-$1.2 billion
Guidance concerns challenge revenue growth objective.
Advances: Increase 2026 revenue guidance to $1.1-$1.2 billion
Revenue beat supports 2026 growth trajectory.
Advances: Increase 2026 revenue guidance to $950-$1,050 million
Q2 results support increased revenue guidance for 2026.
Advances: Increase 2026 revenue guidance
Analysts raising earnings outlook supports revenue growth expectations.
Threatens: Increase 2026 revenue guidance to $950-$1,050 million
Insider selling may signal concerns about future performance.
Advances: Increase 2026 revenue guidance
Positive trial data supports revenue growth expectations.